- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of June 10
The Center for Biosimilars® recaps the top stories for the week of June 10, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 10.
Number 5: The American Medical Association has issued a call for intensified oversight of the pharmacy benefit manager industry.
Number 4: In 3 late-breaking poster presentations at the American Diabetes Association’s 79th Scientific Sessions, researchers presented data on Sanofi’s proposed insulin aspart biosimilar.
Number 3: During the European League Against Rheumatism Annual European Congress of Rheumatology, multiple research teams shared real-world evidence on biosimilar etanercept, SB4.
Number 2: A research letter in JAMA Internal Medicine raises the question of whether there is room for increased FDA transparency about regulatory filings.
Number 1: Experts weighed in on the Biosimilars Forum’s policy proposals that the group says could save the United States billions.
Finally, last week, our e-newsletter asked whether you think other payers will follow UnitedHealthcare’s lead in preferring reference pegfilgrastim over biosimilar options.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
